Alzheimer’s data from Lilly and Biogen converge on small effect for amyloid targeting

Emerging data from anti-amyloid therapies from Eli Lilly and Biogen continue to mirror each other. Whether the consistent findings will bolster both therapies’ cases with regulators, or whether the mAbs are equally likely to fail is anyone’s guess.

What is clear is that the entrenched camps of amyloid believers and doubters will take predictably polarized views...